Side-by-side research comparison of the leading weight-loss peptides studied in Texas laboratories — mechanism, half-life, and documentation.
Written for the Texas research community, this reference brings together the documentation Texas metabolic-research programs compare on weight-related peptides that labs from Austin to Houston, Dallas to San Antonio typically request when qualifying a new lot. Every batch we dispatch from our Texas warehouse ships with the analytical documentation described below.
Weight-loss peptides studied in Texas metabolic-research programs are dominated by GLP-1 and multi-incretin receptor agonists, supplemented by lipolytic fragments such as AOD-9604. The table below summarizes the major documented profiles.
| Compound | Mechanism | Half-life (research) | Reference dose range |
|---|---|---|---|
| Tirzepatide | GIP + GLP-1 agonist | ~5 days | 2.5–15 mg weekly |
| Semaglutide | GLP-1 agonist | ~7 days | 0.25–2.4 mg weekly |
| Retatrutide | GIP + GLP-1 + GCG agonist | ~6 days | Per published trial titration |
| AOD-9604 | Lipolytic hGH fragment | Short | Per published research literature |
Documentation common to all weight-loss research peptides
- HPLC purity ≥98%
- LC-MS confirmed identity
- Counterion content
- Endotoxin per analytical method
Pep Labs 365 ships every research peptide from our Texas facility with a lot-matched Certificate of Analysis, third-party HPLC purity, and LC-MS identity confirmation.
